$MAJI Shareholders - the completion of the preclinical #glioblastoma study of a highly aggressive brain cancer could position the company as a leader in innovative #cancer treatments. An Orphan Drug application could unlock regulatory and financial benefits. Rigorous study design should translate to exceptional credibility w/in the medical & scientific community. Looking forward to this study report validating the exceptional in vitro data that essentially demonstrated significant elimination of cancer stem cells w/ minimal #chemotherapy.
$MAJI Shareholders - the completion of the preclinical #glioblastoma study of a highly aggressive brain cancer could position the company as a leader in innovative #cancer treatments. An Orphan Drug application could unlock regulatory and financial benefits. Rigorous study… pic.twitter.com/OS7zCustr9
Market Data 
Markets 
AI
